Edition:
United Kingdom

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

77.00EUR
11:21am GMT
Change (% chg)

€0.24 (+0.31%)
Prev Close
€76.76
Open
€77.12
Day's High
€77.76
Day's Low
€75.92
Volume
102,135
Avg. Vol
351,539
52-wk High
€81.48
52-wk Low
€60.08

Summary

Name Age Since Current Position

Jean-Christophe Tellier

59 2015 Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Evelyn Diego du Monceau de Bergendal

68 2017 Non-Executive Chair of the Board

Pierre Gurdjian

57 2017 Independent Non-Executive Vice Chairman of the Board

Detlef Thielgen

58 2007 Executive Vice President, Chief Financial Officer, Member of the Executive Committee

Charl van Zyl

51 2017 Executive Vice President, Chief Operating Officer, Member of the Executive Committee

Bharat Tewarie

57 2015 Executive Vice President, Chief Marketing Officer, Member of the Executive Committee

Dhavalkumar Patel

57 2017 Executive Vice President, Chief Scientific Officer, Member of the Executive Committee

Anna Richo

58 2012 Executive Vice President, General Counsel, Member of the Executive Committee

Emmanuel Caeymaex

47 2015 Executive Vice President, Immunology Patient Value Unit Head, Member of the Executive Committee

Jean-Luc Fleurial

53 2017 Executive Vice President, Chief Talent Officer, Member of the Executive Committee

Iris Loew-Friedrich

58 2008 Executive Vice President, Chief Medical Officer and Head of Development and Medical Patent Value Practices, Member of the Executive Committee

Alexander Moscho

48 2017 Executive Vice President, Chief Strategy Officer, Member of the Executive Committee

Pascale Richetta

59 2016 Executive Vice President, Bone Patient Value Unit Head, Member of the Executive Committee

Jeff Wren

55 2015 Executive Vice President, Neurology Patient Value Unit Head, Member of the Executive Committee

Antje Witte

VP Investor Relations

Xavier Michel

Vice President and Secretary General

France Nivelle

VP Global Communication

Dirk Teuwen

VP Corporate Societal Responsibility

Roch Doliveux

61 2017 Non-Executive Director

Charles-Antoine Janssen

47 2012 Non-Executive Director

Cyril Janssen

47 2015 Non-Executive Director

Cedric van Rijckevorsel

48 2014 Non-Executive Director

Alice Dautry

68 2015 Independent Non-Executive Director

Kay Davies

67 2014 Independent Non-Executive Director

Albrecht De Graeve

63 2010 Independent Non-Executive Director

Viviane Monges

55 2017 Independent Non-Executive Director

Norman Ornstein

70 2008 Independent Non-Executive Director

Ulf Wiinberg

59 2016 Independent Non-Executive Director

Biographies

Name Description

Jean-Christophe Tellier

Mr. Jean-Christophe Tellier has served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of UCB S.A. since January 1, 2015. Before that, he was Member of the Executive Committee, Executive Vice President and President of European Operations of the Company from July 1, 2011. He joined the Company from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen's specialty care business in North America, in the areas of endocrinology and neurology. He joined Ipsen in May 2009. He started his career in 1988 in the marketing department of Synthelabo and joined Ciba France as Group Marketing Manager in 1990 and got various marketing & sales position until leading the Marketing & Sales department. In 1997, following the merger of Ciba and Sandoz to form Novartis, he was appointed Head of the Mass Market Business unit in France until the end of 1999 where he became Chief Operating Officer of Novartis France. From 2003 to mid-2006, JC Tellier was Chief Executive Officer (CEO) of Novartis Pharma Belgium and during his tenure was elected president of Pharma.be, the Pharma trade association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, he was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Maryland-based biotechnology company, as Executive Vice President and Chief Commercial Officer. He is physician specialized in rheumatology (University of Paris, France) and followed diverse executive training both at INSEAD and Harvard.

Evelyn Diego du Monceau de Bergendal

Mrs. Evelyn Diego du Monceau de Bergendal has served as Non-Executive Chair of the Board of UCB S.A. since April 27, 2017. Prior to that, she has served as Non-Executive Vice Chairwoman of the Company since June 13, 2006. Between 1984 and June 13, 2006, she served as Non-Executive Director of the Company. She also is Chair of the Governance, Nomination and Compensation Committee as of 2006. She graduated in Applied Economics from Universite catholique de Louvain (the Catholic University of Louvain UCL) in Belgium in 1972. She followed courses in International Relations at the Kennedy School of Harvard University and in Soil Science, Animal Science and Zoology at the Agricultural and Technical College of Farmingdale (New York). She has been Member of the Board of Directors of Financiere de Tubize and member of the Board of Solvay S.A. She has acted as Member of the Nomination and of the Remuneration Committees of Solvay S.A.

Pierre Gurdjian

Mr. Pierre L. Gurdjian has served as Independent Non-Executive Vice Chairman of the Board of UCB S.A. since April 27, 2017. Prior to that, he has served as Non-Executive Independent Director at UCB S.A. since April 28, 2016. He is Member of the Governance, Nomination and Compensation Committee at the Company as of 2016. He is a senior professional in the field of Philanthropy and Education. He is Philanthropy Partner of the RVVZ Foundation since the beginning of 2015, and President of the Board of Directors of the Universite Libre de Bruxelles, effective January 2016. Before he was a Senior Partner at McKinsey and Co. where he was active for nearly three decades. He led the Belgian office between 2005 and 2012. He has been President of the Board of the Universite Libre de Bruxelles. He holds a Masters of Business Administration degree from Harvard Business School, and a Bachelors degree in Engineering from Vrije Universiteit Brussel.

Detlef Thielgen

Mr. Detlef Thielgen has served as Executive Vice President, Chief Financial Officer, Member of the Executive Committee of UCB S.A. since January 2007. He joined the Company in September 2006. He served as Chief Financial Officer of Schwarz Pharma AG and Managing Director of Schwarz Pharma Operations covering the worldwide manufacturing and supply chain functions. He also took on the responsibility of Vice President Finance & Administration/Chief Financial Officer at Schwarz Pharma Inc./States of America. In 1999, he was appointed Managing Director of the worldwide Manufacturing and Supply Chain Operations for Schwarz Pharma AG. From 2002 to 2007 he was Chief Financial Officer and later also Chief Executive Officer for Schwarz Pharma AG before being appointed in November 2007 to his current role. He studied economics and received his diploma from the University of Wuppertal.

Charl van Zyl

Mr. Charl van Zyl has served as Executive Vice President, Chief Operating Officer, Member of the Executive Committee of UCB S.A. since March 1, 2017. Since 2014, he has served as Executive Vice President, Global Commercial Head and Head of Latam/Canada at BSN Medical. From 2009 to 2013 he worked for Bauch & Lomb as Executive Vice President, President of EMEA and from 2007 to 2009 he was Chief Executive Officer of Jado Technologies (Biotech). From 2004 to 2007 he served at Novartis as Head Marketing and Sales EMEA and Head of Global Marketing. Moreover, he was Marketing Manager Diabetes Care and Neurosciences Latam/Canada and South Africa Marketing Manager Japan at Eli Lilly from 1995 to 2004. In 1991 he graduated from University of Cape Town, South Africa in Medical Biochemistry and in 1999 in Business Administration – executive program from the same university.

Bharat Tewarie

Dr. Bharat Tewarie has served as Executive Vice President, Chief Marketing Officer, Member of the Executive Committee of UCB S.A. since March 2015. He joined the Company in March 2015. He received an MBA from Webster University in 1991, and a Masters degree from Universiteit Utrecht in 1986. He joined UCB with 27 years of experience in the biotech industry. He has acquired world-wide expertise while leading global business unit teams to great success. His past experience in domains such as immunology and neurology are a great match to UCB’s core focus areas. His knowledge of markets around the world is also key to helping UCB prepare for future product launches. Trained as a medical doctor (MD), he also has background in multiple aspects of pharmaceutical management, including P&L responsibility, business development, sales, global marketing, clinical research and medical affairs. At UCB he heads the Global Strategic Marketing Practice and is a member of the Executive Committee. Key positions Prior to UCB: 2012 – 2014 EMD Serono Inc.: Senior Vice President, Head of the Global Business Franchise Neurology and Immunology and of the Global Business Franchise Medical Devices 2010 – 2011 Merck Serono SA: Senior Vice President, Head of Global Business Unit Fertility & Endocrinology 1998 – 2010 During this timeframe, Bharat held various leadership positions at Serono International SA, Serono Inc and EMD Serono in Endocrinology and Reproductive Health covering areas such as global sales and marketing, US business unit management and business development Prior to this, he built up his global and local experience with other companies: Roche Pharma and Boehringer Ingelheim.

Dhavalkumar Patel

Mr. Dhavalkumar (Dhaval) Patel has served as Executive Vice President, Chief Scientific Officer, Member of the Executive Committee of UCB S.A. since October 2017. Dhaval Patel leads UCB’s research organization with the main goal of bringing scientific innovation to patients and helping them live the life they choose. Dhaval Patel is a medical doctor and holds a PhD in Microbiology and Immunology. He comes to UCB from Novartis, based in their headquarters in Basel, Switzerland, where for 11 years he led various biomedical research teams in areas of neurology, autoimmunity, transplantation and inflammation. In 2010, he became the Head of Research for the Novartis Institutes for BioMedical Research (NIBR) Europe. For 12 years prior to crossing into industry, Dhaval made a strong mark in the halls of academia and research, specifically at Duke University Medical Center and the University of North Carolina (UNC) at Chapel Hill in North Carolina in the US. He authored and co-authored over 100 thought-leading publications and presentations. Key positions: Prior to UCB, Dhaval held the following positions: 2006 - 2017 Novartis International AG, Head of Research of the Novartis Institutes for BioMedical Research Europe, Global Head of Autoimmunity, Transplantation and Inflammation at the Novartis, Institutes for BioMedical Research; 2003 - 2006 University of North Carolina at Chapel Hill, USA, Director, Thurston Arthritis Research Center, Chief of the Rheumatology, Allergy and Immunology division, Professorships in the Department of Medicine, Microbiology and Immunology; 1994 – 2003 Duke University Medical Center, USA, Chief of the Allergy and Immunology division, Professorships in the Department of Medicine and Immunology. Education: Dhaval Patel graduated from Duke University where he completed a Bachelor in Science degree, an MD and a PhD in Microbiology and Immunology.

Anna Richo

Ms. Anna S. Richo has served as Executive Vice President, General Counsel, Member of the Executive Committee of UCB S.A. since November 1, 2012. She joined the Company on November 1, 2012. She joined UCB from Amgen Inc., where she was Senior Vice President and Chief Compliance Officer. Prior to that, she was Vice President, Law responsible for management of Amgen’s corporate litigation and law department operations, and upon joining Amgen in 2003, she was responsible for corporate law activities. From 1991 - 2003, she was at Baxter Healthcare Corporation, holding a number of positions with increasing responsibility including Vice President, Law for the Bio Science business and was previously Chief Litigation Counsel for the company. Prior to joining Baxter, Ms. Richo was an attorney for The NutraSweet Company, and was an associate with the Chicago-based law firm of Peterson & Ross. Ms. Richo received her Juris Doctor degree from DePaul University, College of Law and her Bachelor of Science degree in Industrial and Labor Relations from Cornell University. She is admitted to practice in Illinois and California. She formerly served on the Board of Directors of Cytyc Corporation a medical diagnostics company, from 1998 - 2003, and was Member of the Audit and Finance Committees.

Emmanuel Caeymaex

Mr. Emmanuel Caeymaex has served as Executive Vice President, Immunology Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 2015. He joined UCB in March 1994. He leads the understanding of patient needs, the development and commercialization of solutions which create value for people suffering from auto-immune disorders such as bowel diseases, skin conditions and lupus. Over the last 20 years Emmanuel has been instrumental in advancing UCB’s transformation into a global company focused on patients with severe diseases. Prior to this appointment he led the Cimzia Global Patient Solutions team. Emmanuel formerly served as President of UCB Japan Co Ltd. from September 2006 to June 2011 and on the Global Operations Committee. He previously contributed to build UCB’s leadership position in epilepsy, successively as Global Brand Manager Keppra, UK Business Unit Head, and Vice President Global Marketing for Central Nervous System products. Prior to 1999, Emmanuel established and ran UCB’s operations in several Asia-Pacific markets for which he was awarded as Laureate of the Prince Albert Fund. He received a Business Engineer Master of Science degree from Universite Catholique de Louvaine, Belgium, a Masters in International Management from the Global Alliance in Management Education (former Community of European Management Schools CEMS) and has been continuing his executive leadership development journey at INSEAD.

Jean-Luc Fleurial

Mr. Jean-Luc Fleurial has served as Executive Vice President, Chief Talent Officer, Member of the Executive Committee of UCB S.A. since 2017. EXPERIENCE: Over 20 years of experience in building and implementing talent strategy across geographies and businesses, mainly with Procter&Gamble and Bristol Myers Squibb. He is passionate about people and organization development, building inclusive and innovative culture and is inspired every day by the mission to help patients. Having recently joined UCB, Jean-Luc is highly energized to have the opportunity to contribute to UCB’s Patient Value Strategy, and is delighted to support the development of a company culture and talent strategy that will bring even more innovative medicines to meet patients’ unmet needs. Key dates in Jean-Luc’s career: 2017 - Joins UCB as Chief Talent Officer He also heads UCB’s Global Communications and Company Reputation department, and the Corporate Societal Responsibility team. Prior to UCB: 2008 - 17 Various positions at Bristol-Myers Squibb, including Vice President, Human Resources, US commercial, World Wide Commercialization, Policy and Operations; 1998 - 8 Various positions at Procter & Gamble in Europe, making a professional move from Manufacturing to Human Resources after 5 years and supporting different consumer businesses in France and Nordic countries. Education: Jean-Luc received a Master degree from Chemical Engineering School of Nancy of Nancy-Universite, is a qualified executive coach and MBTI practitioner.

Iris Loew-Friedrich

Prof. Dr. Iris Loew-Friedrich has served as Executive Vice President, Chief Medical Officer and Head of Development and Medical Patent Value Practices, Member of the Executive Committee of UCB S.A. since March 2008. She joined the Company in September 2006. Prior to taking on her current role in March 2008, she was the Company's Global Head of Development, during which time she oversaw clinical development of neurology and immunology products. From 2001 to 2009, she also served as the head of Global Research and Development for Schwarz Pharma, which the Company moved to acquire in 2006. She was also on the Schwarz Pharma Executive Board. Dr. Loew-Friedrich held several medical and R&D roles, including Vice-President and Head of Global Projects at BASF Pharma, Ludwigshafen, Germany; Vice-President, Head of Global Clinical Management, HMR/Aventis, and Therapeutic Area Head Rheumatology and Bone Diseases, Hoechst/HMR, Bridgewater, New Jersey. She received her medical license and her Doctorate in Philosophy from Universitat Frankfurt am Main, Frankfurt, Germany, in 1985. From 1985 to 1992, she was the staff physician at the Department for Internal Medicine at the Frankfurt University Medical School, with sub-specialties in immunology, nephrology, and transplantation medicine. She is board-certified in internal medicine and olds a professorship at Frankfurt University Medical School.

Alexander Moscho

Mr. Alexander Moscho has served as Executive Vice President, Chief Strategy Officer, Member of the Executive Committee of UCB S.A. since October 2017. As Head of Corporate Strategy & Business Development, Alexander will work closely with UCB’s Executive Committee to provide strategic guidance and alignment across the organization, developing recommendations and scenarios to support UCB’s short- and longer term goals. Alexander comes to UCB from Bayer where he was General Manager for the UK & Ireland since 2014. His previous position at Bayer was Head of Corporate Development, a role which he held for several years. In this capacity, he was responsible for the company’s corporate global strategy and portfolio management, as well as innovation and investment projects. Before that he was the Head of Bayer’s In-House Consulting, which he developed into a global service provider. Prior to Bayer, Alexander was Associate Principal at McKinsey & Company. Key positions: Prior to UCB, Alexander held the following positions: 2014 - 2017 Bayer, CEO Bayer UK/ Ireland; 2010 - 2014 Bayer, Head of Corporate Development; 2006 - 2010 Head of Business Consulting of Bayer Business Services; 1996 - 2006 McKinsey & Company, Associate Principal, Focus on projects in Pharma, Biotechnology and Healthcare. Education: Alexander holds a PhD in Biotechnology (summa cum laude) from the University of Munich and a Master of Science in Biotechnology from Deutsche Muellerschule Braunschweig (DMSB) in Germany. He worked as a visiting scholar in the Department for Analytical Chemistry at Stanford University/USA and lectured on bio-entrepreneurship as a Visiting Professor at Danube University in Austria.

Pascale Richetta

Ms. Pascale Richetta has served as Executive Vice President, Bone Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 1, 2016. She has over 20 years of experience in the pharma and biotech industry. She has acquired commercial experience managing both traditional pharmaceuticals and complex biologics. Her experience and knowledge of markets around the world is key to helping UCB prepare for future product launches. Trained as a medical doctor (MD), Pascale Richetta leads UCB’s Bone Patient Value Unit. One of her main missions is to take UCB’s investigational osteoporosis drug through the next steps in its development and prepare for its potential launch upon approval. Key positions: Prior to UCB, Pascale held the following positions: 2013 – Present AbbVie Vice President, Western Europe and Canada In charge of a multi-billion specialty care portfolio including key biologic products Covering 19 affiliates and over 3000 staff 2004 – 2013 Abbott: Vice President, Western Europe and Canada 1994 - 2004 GSK Operations Director in France and Europe in charge of the Central Nervous System franchise 1990-1994 Ipsen Marketing Manager, France 1987-1990 Product Manager, France. Education: 1985 Universite de Poitiers, France M.D. Prior trade association engagement EFPIA: Vice Chair of the Executive Committee, member of the Board EBE: Member of the Board Europa BIO: Member of the Board.

Jeff Wren

Mr. Jeff Wren has served as Executive Vice President, Neurology Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 2015. He joined the Company in October 2010. In his current role, he heads UCB’s neurology patient value unit, neurology being one of UCB’s two main therapy areas. He is responsible for the entire value chain of UCB’s neurology portfolio, from development through medical, market access, sales and marketing. Before taking on his current role he was Senior Vice President UCB North America. He was responsible for providing leadership and strategic direction to all aspects of the organization’s operations in both the US and Canada. Prior to this he was Vice President of UCB’s Managed Markets and Trade Relations in the US and head of UCB’s Canada operations. He has served as the Chairman of the Board for UCB, Inc. in the US as well as UCB Canada. He has been member of the board of directors for BIO International, as well as Vice-chair and executive committee member for Georgia Bio association group. He has been member of the board of advisors for the Metro Atlanta Chamber of Commerce. He holds Bachelor of Science in Biology from Missouri Southern State University, Joplin, Missouri. At INSEAD he also completed Executive Business Program.

Antje Witte

Xavier Michel

France Nivelle

Dirk Teuwen

Roch Doliveux

Dr. Roch Doliveux has served as Non-Executive Director of UCB S.A. since April 27, 2017. He served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of the Company between January 1, 2005 and December 31, 2014. He was Deputy Chairman of Executive Committee, Director General of the Pharma Sector of the Company between October 2003 and January 1, 2005. He is Doctor in Veterinarian Medicine from Maisons-Alfort (France), Mr. Doliveux is also Laureate of the Faculty of Medicine, Creteil, and holds a Masters of Business Administration from INSEAD or Institut Europeen d'Administration des Affaires, France with distinction. He joined the pharmaceutical industry early, first at Ciba-Geigy (now Novartis) in Switzerland, in Peru and in France, and then at Schering-Plough Corporation in various positions, including President of Schering-Plough International. Then, Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer (CEO) of Pierre Fabre Pharmaceuticals. Mr. Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, Member of the Board of Stryker Corporation in the United States, as well as a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Union and EFPIA, WELBIO (Walloon Institute for Life Lead Sciences), the INSEAD International Council and Chairman of the Caring Entrepreneurship Fund (King Baudouin Foundation).

Charles-Antoine Janssen

Mr. Charles-Antoine Janssen has served as Non-Executive Director of UCB S.A. since April 2012. He is Member of the Audit Committee of the Company (as of 2015). He joined the Company in 2001 where he held several management positions at global and local levels. Among other responsibilities he was head of Business Development, General Manager of Austria and India, and most recently managed International Major Markets Operations. Prior to the Company, he worked for Merrill Lynch in London from 1996-2000 where he was Vice-President Equities Research then Vice-President New Derivatives Europe. He holds a bachelor of Laws degree from Brussels University (ULB) and an AMP from Harvard Business School.

Cyril Janssen

Mr. Cyril Janssen has served as Non-Executive Director of UCB S.A. since 2015. In 1993, he joined Can Do SA, an audio-visual and event company and became one of the key managing partners and a Board Member before selling the company to the German Group Procon in 2006. He leads the Financiere Eric Janssen as well as Nikita which provides loans and equity capital to SMEs. He has been Board Member of Financiere de Tubize SA, Imbra, Elmina, AGV, Generous and Caring Entrepreneurship Fund. Mr. Janssen was involved in the “Creation and Growth Program” of the Solvay Business School with the aim to accompany and train young entrepreneurs.

Cedric van Rijckevorsel

Mr. Cedric van Rijckevorsel has served as Non-Executive Director of UCB S.A. since 2014. A Chartered Financial Analyst from the CFA Institute, he also holds a Commercial Engineer degree from Saint Louis University. He started his career in Bank Brussels Lambert (ING Group) followed by Generale Bank (Fortis Group). In 1996 he joined Lombard Odier & Cie, Private Bankers in Switzerland and in 2001 became Senior Portfolio Manager at 3A, a leading institutional alternative investment firm and division of Bank Syz in Switzerland. In 2004 he founded IDS Capital SA in Geneva of which he became Managing Director and after spending close to 10 years building and growing IDS Capital SA in Switzerland, Cedric set up IDS Capital (UK) Ltd in London of which he is a Director and the CEO. He remains a Director of IDS Capital SA Geneva. He has been Member of the Board of Barnfin SA and Financiere de Tubize SA.

Alice Dautry

Prof. Alice Dautry has served as Independent Non-Executive Director of UCB S.A. since 2015. She is Member of the Scientific Committee of the Company as of 2015. She has been President of the Institut Pasteur (2005 to 2013). Trained as a physicist in Paris and as a molecular biologist at the University of New York and the National Institutes of Health, she has been a visiting scientist at the Massachusetts Institute of Technology. She is the author of some 130 publications in international scientific journals. She has been member of the Academy of Sciences Leopoldina (Germany) and the Academy of Technologies (France). She is or has been a member of Board and scientific councils of research organizations and private companies, including Institute of Science and Technology Austria (Austria), Drugs for Neglected Diseases Initiative (Switzerland), Ch Hansen (Denmark), KLM (the Netherlands), the External Reference Group for Health Research Strategy of the WHO, Instituts Pasteur in the world (Dakar; Shanghai; Seoul). She holds a Doctorate in Philosophy degree from Universite de Paris, a Master of Science degree in Molecular Biology from State University of New York, and a Master of Science degree in Chemistry from Universite de Paris.

Kay Davies

Ms. Kay Davies has served as Independent Non-Executive Director of UCB S.A. since 2014. She is Chairperson of the Scientific Committee of the Company (as of 2014). She is Member of the Governance, Nomination and Compensation Committee of the Company with effect from April 27, 2017. She has 20 years of scientific research experience. She is a founding fellow of the UK Academy of Medical Sciences and was elected a Fellow of the Royal Society in 2003. She has been Director of the Biotech Growth Trust, has been a Governor of the Wellcome Trust since 2008 and became Deputy Chairman in October, 2013. Professor Davies was made Dame Commander of the British Empire for services to science in 2008. She has also been involved as independent scientific advisor on UCB’s Science Advisory Board since 2012.

Albrecht De Graeve

Mr. Albrecht (Bert) De Graeve has served as Independent Non-Executive Director of UCB S.A. since April 29, 2010. He is Chairman of the Company's Audit Committee (as of 2015), Member of the Audit Committee as of April 29, 2010. He has been Chief Executive Officer of the Bekaert Group since May 2006. From 2002 until May 2006 he was Chief Financial and Administration Officer and General Secretary of the Group. He started his career in 1980 with Arthur Andersen & Co and joined Alcatel Bell in 1982. In 1991 he became General Manager Shanghai Bell Telephone Equipment Mfg. Cy in Shanghai. In 1994 he was appointed Vice President, Director Operations, Alcatel Trade International and later Director International Affairs, Alcatel Alsthom in Paris. In 1996 he became Managing Director of the Flemish Public Radio & TV Broadcaster (VRT). He holds a Master in Law from the University of Ghent (1980), studied Financial Management at IPO (Antwerp) and became Master in Tax Management at VLEKHO (Brussels). Mr. De Graeve has been Member of the International Business Leaders' Advisory Council for the Mayor of Shanghai (IBLAC), President of the Flanders-China Chamber of Commerce, Member of the Advisory Board of the Conference Board China Center for Economics and Business in Beijing, Member of the Board of Directors of UCB and Member of the Board of the Concours Reine Elisabeth. He received a Masters degree in Law from Universiteit Gent in 1980. He also holds a Masters degree in Tax from Vlaamse Economische Hogeschool (VLEKHO), and a Masters degree in Financial Management from Instituut voor Postuniversitair Onderwijs, Antwerp (IPO).

Viviane Monges

Ms. Viviane Monges has served as Independent Non-Executive Director of UCB S.A. since April 27, 2017. EXPERIENCE: 30 years in Finance functions mostly in the pharmaceutical industry (Wyeth, Novartis, Galderma). MAIN EXTERNAL APPOINTMENTS: Member of the strategic Board of Neomedlight.

Norman Ornstein

Dr. Norman J. Ornstein has served as Independent Non-Executive Director of UCB S.A. since April 24, 2008. He is resident scholar at the American Enterprise Institute for Public Policy Research based in Washington D.C., United States. He serves as senior counselor to the Continuity of Government Commission and as election analyst for CBS News. He writes in several United States newspapers and other publications related to United States politics. Mr. Ornstein has a Bachelor of Arts from the University of Minnesota, from which he also received an honorary Doctor of Laws degree, and a Master of Arts and Doctorate in Philosophy from the University of Michigan. He served as Member of the Board of Public Broadcasting Service (PBS) and is currently on the Board of Directors of the Campaign Legal Center as well as of the Board of Trustees of the United States Capitol Historical Society and the Center for United States Global Engagement. He holds a Doctorate in Philosophy degree from University of Michigan, a Master of Arts degree from University of Michigan, a Bachelor of Arts from University of Minnesota, and a degree in Law from University of Minnesota.

Ulf Wiinberg

Mr. Ulf Wiinberg has served as Independent Non-Executive Director of UCB S.A. since April 28, 2016. He is Member of the Audit Committee of the Company (as of 2016). He is a pharmaceutical industry professional. He started as a sales representative at Lederle Laboratories in Sweden, which later was acquired by Wyeth. At Wyeth, he was President of the global consumer health care business, and later President for the European business and strategically responsible for biotechnology and vaccines. He served as a member of the management committee from 2002-2008. From 2008 to end of 2014, he was the CEO of Lundbeck, a Danish company focusing on brain diseases. During his career, he has worked on development and in production of pharmaceutical products and vaccines that can make a big difference for patients. He has also served on the boards of the industry associations for the pharmaceutical and consumer healthcare business, Pharma, Efpia and WSMI. He has been Chairman of the Board of Avillion, Chairman of the Board of Hansa Medical, Board member at Alfa Laval and Board member at Agenus.